Cybin Inc., doing business as Helus Pharma, filed interim financial statements for the three months ended June 30, 2026. The company reported a net loss of $47.8 million and cash reserves of $166.4 million. During the quarter, Helus Pharma completed an underwritten offering of 10,309,280 common shares at $4.85 per share, generating approximately $46.5 million in net proceeds. The company also announced that enrollment for its pivotal Phase 3 APPROACH trial of HLP003 was completed with 223 participants on July 21, 2026. Helus Pharma operates as a clinical-stage pharmaceutical company developing novel serotonergic agonists for mental health conditions.
